Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders

A method of treating a symptom of a disease or disorder selected from the group consisting of:

• premenstrual dysphoric disorder, pre-menstrual syndrome, a psychotic disorder, brief psychotic disorder, schizophrenia, psychotic mood disorder, attention deficit disorder with hyperactivity, attention deficit disorder without hyperactivity, obesity, eating disorders, anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine addiction, alcohol addiction, sexual dysfunction, sexual dysfunction related illnesses, acute pain syndrome, chronic pain syndrome, fibromyalgia, arthritis, chronic low back pain, trigeminal neuralgia visceral pain syndromes, irritable bowel syndrome, noncardiac chest pain, functional dyspepsia, interstitial cystitis, essential vulvodynia, urethral syndrome, orchialgia, temperomandibular disorder, atypical face pain, migraine headache, tension headache, functional somatic disorders, chronic fatigue syndrome, neurologic disorders, seizure disorder, Tourette Syndrome, Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, subcortical dementia, nonsubcortical dementia, Tardive Dyskinesia, Multiple Sclerosis, Rett Syndrome and amyotrophic lateral sclerosis comprising contacting a patient with an effective amount of a compound with the following structure:
• wherein, m is 0, 1, 2, 3 or 4;
• wherein, n is 1, 2, 3, or 4;
• wherein A and B are H;
• and wherein R1 is selected from the group consisting of:
• wherein X is oxygen, and
• an unsymmetrical amine group of the formula
• wherein R3 and R4 are independently selected from the group consisting of H, a C1-C8 branched alkyl, and a C1-C8 linear alkyl, or
• a pharmaceutically acceptable salt thereof.